Virpax And MedPharm Advance Diclofenac Spray
Transdermal Osteoarthritis Treatment To Be Submitted Via 505(b)(2) Pathway In US
Virpax Pharmaceuticals and partner MedPharm say they have made progress towards filing through the US 505(b)(2) hybrid pathway a diclofenac spray for treating osteoarthritis of the knee.
You may also be interested in...
After a 12-month period that has seen Stada make significant investments in generics, biosimilars and consumer healthcare, CEO Peter Goldschmidt tells Generics Bulletin that the firm does not intend to stop there, as it pursues both organic and inorganic growth opportunities.
A US bill aimed at promoting biosimilars by encouraging greater prescribing rates and creating a shared savings demonstration program for biosimilars has been warmly welcomed by the AAM.
In the wake of the revelation that the US has secured rights to almost all of Gilead’s remdesivir supplies through September 2020, compulsory licensing had been raised as a possible way for countries to procure versions of the COVID-19 treatment. However, Medicines for Europe has cautioned that the procedure will not be practical to apply in Europe.